ClinicalTrials.gg

Program

marstacimab

Also written as “PF-06741086”, “MARSTACIMAB” and “Marstacimab PFP”.

Its studies are mostly in Hemophilia A, led by Pfizer.

Furthest: phase 3, since May 2, 201910 company-led studies, 4 open or runningNext primary completion: May 5, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer104 open or runningphase 3since May 2, 2019Aug 3, 2015May 5, 2027phase 1 · NCT06703606

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 3, 2015First study: phase 1 study in HealthyFirst studyNCT02531815 · 41 enrolled · Belgium
  2. Nov 23, 2016Phase 2 study in Hemophilia ANCT02974855 · 27 enrolled · United States, Chile, Croatia and more
  3. Nov 30, 2017Phase 2 study in Hemophilia ANCT03363321 · 20 enrolled · United States, Brazil, Chile and more
  4. May 2, 2019Phase 3 study in Hemophilia ANCT03938792 · 188 enrolled · United States, Bulgaria, Canada and more
  5. Mar 26, 2021Phase 1 study in Hemophilia ANCT04832139 · 22 enrolled · Belgium
  6. Apr 16, 2021Phase 1 study in Hemophilia ANCT04878731 · 6 enrolled · China
  7. Nov 11, 2021Phase 3 study in Hemophilia ANCT05145127 · 245 planned · United States, Argentina, Australia and more
  8. Oct 27, 2022Phase 3 study in Hemophilia ANCT05611801 · 100 planned · United States, Argentina, Australia and more
  9. Nov 21, 2024Phase 1 study in Hemophilia ANCT06703606 · 15 planned · United States, India, Turkey (Türkiye)
  10. Oct 21, 2026Phase 3 study in Hemophilia ANCT07923981 · 95 planned · United States

Ahead

  1. May 5, 2027Primary completion: phase 1 study in Hemophilia ANCT06703606
  2. Sep 10, 2028Primary completion: phase 3 study in Hemophilia ANCT05611801
  3. Jul 2, 2029Primary completion: phase 3 study in Hemophilia ANCT07923981
  4. Jul 31, 2030Primary completion: phase 3 study in Hemophilia ANCT05145127

TargetBeta

TFPI →read by rule
“Tissue factor pathway inhibitor inhibitor”ChEMBL 37, by rule

Other programs on TFPI

ProgramCompanyFurthest phaseStudies
andexanet alfaruleAstraZenecaphase 414

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07923981Hemophilia A · United States3RecruitingJul 2, 202995
NCT06703606Hemophilia A · United States, India, Turkey (Türkiye)1RecruitingMay 5, 202715
NCT05611801Hemophilia A · United States, Argentina, Australia and more3RecruitingSep 10, 2028100
NCT05145127Hemophilia A · United States, Argentina, Australia and more3RecruitingJul 31, 2030245
NCT04878731Hemophilia A · China1CompletedAug 10, 20216
NCT04832139Hemophilia A · Belgium1TerminatedNov 22, 202122
NCT03938792Hemophilia A · United States, Bulgaria, Canada and more3CompletedApr 29, 2025188
NCT03363321Hemophilia A · United States, Brazil, Chile and more2CompletedAug 5, 202020
NCT02974855Hemophilia A · United States, Chile, Croatia and more2CompletedDec 3, 201827
NCT02531815Healthy · Belgium1CompletedJul 201641

How it is read

Names in the registry

  • “PF-06741086”, 9 entries
  • “marstacimab”, 2 entries
  • “MARSTACIMAB”, 1 entry
  • “Marstacimab PFP”, 1 entry
  • “Marstacimab PFS”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.